Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Further thoughts on 'cell kill' in acute leukemia.

Z A Arlin1, W Hiddemann, E Feldman

  • 1New York Medical College, Valhalla.

Acta Haematologica
|January 1, 1991
PubMed
Summary

Intensifying chemotherapy for acute myelogenous leukemia (AML) shows limited survival benefits and increased toxicity. New induction strategies and targeted therapies are needed for better long-term outcomes in AML patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selecting a PRO-CTCAE-based subset for patient-reported symptom monitoring in prostate cancer patients: a modified Delphi procedure.

ESMO open·2023
Same author

Preliminary Experience with Short Course High-Dose Mitoxantrone in Combination with High-Dose Cytarabine in Patients with Acute Leukemia and Blastic Phase of Chronic Myelogenous Leukemia.

Leukemia & lymphoma·2016
Same author

Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule.

Leukemia & lymphoma·2016
Same author

Probabilistically Perfect Cloning of Two Pure States: Geometric Approach.

Physical review letters·2016
Same author

Familial dyslexia: genetic and medical findings in eleven three-generation families.

Annals of dyslexia·2013
Same author

The safety and efficacy of gi endoscopy in patients with acute-leukemia - a review of 27 cases.

International journal of oncology·2011

Area of Science:

  • Hematology
  • Oncology
  • Leukemia Research

Background:

  • Traditional acute myelogenous leukemia (AML) therapy offers limited long-term survival rates, with less than 20% of patients achieving cure.
  • Intensified postinduction chemotherapy has yielded minimal improvements in survival and is associated with increased toxic-death rates.

Purpose of the Study:

  • To explore novel induction regimens for acute myelogenous leukemia (AML) to reduce tumor burden.
  • To investigate the potential of 'enhancers' to improve the efficacy of induction chemotherapy.
  • To determine if reducing tumor burden and optimizing supralethal therapy timing can increase cure rates.

Main Methods:

  • Review of current acute myelogenous leukemia (AML) treatment protocols.
  • Analysis of the impact of intensified chemotherapy on survival and toxicity.

Related Experiment Videos

  • Exploration of the role of 'enhancers' in induction therapy.
  • Discussion on the significance of minimal residual disease monitoring.

    • Main Results:

    • Current intensified chemotherapy for AML offers marginal survival benefits.
    • Increased toxic-death rates accompany intensified chemotherapy regimens.
    • Lowering tumor burden and strategic supralethal therapy show potential for improved cure rates.

    Conclusions:

    • More effective induction regimens are crucial for eradicating leukemia burden in AML.
    • The use of 'enhancers' alongside induction therapy may improve treatment outcomes.
    • Minimal residual disease measurement is key for selecting appropriate postinduction therapy in AML.